CLEC10A as a Prognostic Marker and Its Relationship with Immune Infiltration in Breast Cancer

Abstract

Background: The C-type lectin domain family 10 member A (CLEC10A), which is an affiliate of the C-type lectin receptors (CLRs), performs a crucial function in regulating adaptive and innate immunity and has demonstrated tremendous promise as a target for cancer immunotherapy. Nevertheless, there has been no functional study of CLEC10A in breast cancer (BRCA) prognosis risk, immunotherapy, or any other treatment. Methods: The Gene Expression Profiling Interactive Analysis (GEPIA) and the Tumor IMmune Estimation Resource (TIMER) were used to assess CLEC10A expression in BRCA and to look at immunohistochemistry in the Human Protein Atlas (HPA). PrognoScan, GEPIA, Oncolnc and Kaplan–Meier (KM) plotter were employed to assess the prognostic impact of CLEC10A on BRCA. TIMER, GEPIA 2021, and TISIDB were utilized to assess the impact of CLEC10A on the immune microenvironment and cBioPortal was used to assess the alteration of CLEC10A, both in BRCA. Results: We found that C-type lectin domain family 10 member A (CLEC10A) expression was reduced in BRCA and was associated with poorer survival. We found that CLEC10A was 0.8% genetically altered in BRCA, with profound deletion being the most common alteration. Furthermore, CLEC10A expression was shown to be strongly linked to a number of different tumor-infiltrating immune cells (TIICs), and we found that CLEC10 was closely related to PDCD1, CD244, CD27, CD48, HLA-DOA, HLA-DPA1, XCL2, CCL17, CXCR3 and CCR7 among others. Conclusions: CLEC10A expression has a high prognostic significance and may be a potential biomarker for immunotherapeutic approaches in BRCA.